In Norway, the breast cancer incidence increased by 50% in the 1990 s, during a period with initiation of mammography screening as well as a fourfold increase in use of menopausal hormone therapy (HT). After 2002, the HT use has dropped substantially; however, the breast cancer incidence has declined only marginally. How much mammography screening contributed to the breast cancer incidence increase in the 1990 s compared with HT use and specifically different types of HT use, has thus been discussed. Whether HT affects the incidence of subtypes of breast cancer differently has also been questioned. We have linked individual data from several national registries from 2004 to 2009 on 449,717 women aged 50-65 years. 4597 cases of invasive cancer and 681 cases of ductal carcinoma in situ (DCIS) were included in the analysis. We used Cox regression to estimate hazard ratio (HR) as a measure of the relative risk of breast cancer associated with use of HT. The HRs associated with prescriptions of HT for more than 1 year were 2.06 (1.90-2.24) for estrogen and progesterone combinations, 1.03 (0.85-1.25) for systemic estrogens, and 1.23 (1.01-1.51) for tibolone. Invasive lobular carcinoma was more strongly associated with use of estrogen and progesterone combinations, HR = 3.10 (2.51-3.81), than nonlobular carcinoma, HR = 1.94 (1.78-2.12). The corresponding value for DCIS was 1.61 (1.28-2.02). We estimated the population attributable fraction to 8.2%, corresponding to 90 breast cancer cases in 2006 indicating that HT use still caused a major number of breast cancer cases.
Notes
Cites: Int J Cancer. 2012 Jun 15;130(12):2930-821732346
Cites: BMJ. 2012;344:e29922290099
Cites: Breast Cancer Res Treat. 2013 Feb;137(3):915-2523315265
Cites: Breast Cancer Res Treat. 2014 Jun;145(2):481-924748570
Cites: J Natl Cancer Inst. 2000 Feb 16;92(4):328-3210675382
Cites: JAMA. 2000 Jan 26;283(4):485-9110659874
Cites: Lancet. 2008 Aug 23;372(9639):608-1018722851
Cites: JAMA. 2002 Feb 13;287(6):734-4111851540
Cites: JAMA. 2002 Jul 17;288(3):321-3312117397
Cites: Cancer. 2002 Dec 15;95(12):2455-6412467057
Cites: Cancer Causes Control. 2003 Apr;14(3):225-3312814201
Cites: Lancet. 2003 Aug 9;362(9382):419-2712927427
Cites: BMJ. 2004 Apr 17;328(7445):921-415013948
Cites: Int J Cancer. 2004 Oct 20;112(1):130-415305384
Cites: Int J Cancer. 1999 May 5;81(3):339-4410209946
Cites: Lancet. 1997 Oct 11;350(9084):1047-5910213546
Cites: Int J Cancer. 2006 Jun 15;118(12):3112-716395702
Cites: Eur J Epidemiol. 2007;22(7):447-5517594526
Cites: JAMA. 2008 Mar 5;299(9):1036-4518319414
Cites: BMJ. 2009;339:b258719589821
Cites: Breast J. 2012 Nov-Dec;18(6):549-5623002918